-
four binding interactions of aNF to P450 3A4 are suggested by this study, one of which may be newly recognized and which could affect studies of drug oxidations by this important enzyme
-
We analyzed tacrolimus trough concentrations in 1345 adult EA recipients with two CYP3A5 LoF alleles in a genome-wide association study. Only CYP3A4*22 was identified and no additional variants were genome-wide significant
-
heterozygous for CYP 3A4*22 partially explained the early-onset and severity of myelosuppression in patient taking Sunitinib for kidney neoplasm
-
Experimental in silico and in vivo studies confirmed that the original Russian benzodiazepine phenazepam was the substrate of CYP3A4 isoenzyme.
-
The CYP2C19 phenotype is not predicted by the number of functional alleles of CYP2C19 and CYP3A4 genes.
-
The in vitro studies of Pristimerin (PTM) with CYP isoforms indicate that PTM has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2, 3A4 and 2C9.
-
Apigenin showed reversible inhibition, acacetin, and chrysin showed combined irreversible and reversible inhibition while chrysin dimethylether, isorhamnetin, pinocembrin, and tangeretin showed pure irreversible inhibition. These results alert on possible flavonoiddrug interactions on the level of CYP3A4
-
This patient should be regarded as a CYP3A-poor metabolizer.
-
spectroscopic studies clarified the heteroactivation of CYP3A4 caused by efavirenz with a proper affinity to the peripheral site
-
The genetic polymorphisms of the multi-drug resistance-1 (MDR-1) and human cytochrome P450 3A (CYP3A4 and CYP3A5) genes were analyzed and compared between steroid sensitive, steroid resistant and control groups.
-
this meta-analysis suggests that the CYP3A4*1B polymorphism might play a modest role in susceptibility to cancer, especially for leukemia.
-
JNK is a novel mechanistic regulator of CYP3A4 induction by PXR.
-
The other four metabolites were almost exclusively metabolized by CYP3A4.
-
It observed an increase in the activity of CYP3A following but not during pregnancy when measured using the 4beta-hydroxycholesterol/cholesterol ratio. In addition, based on our results, it suggestes that the plasma 4beta-hydroxycholesterol/cholesterol ratio be used to measure CYP3A activity in pregnant women.
-
These findings also suggest that EGF may be an important regulator of CYP3A4 expression in vivo.
-
our results indicate that a significant level of MDR1 mRNA, but not CYP3A4 mRNA, is intrinsically present before chemotherapy in advanced STS tumors.
-
A weak-to-moderate CYP3A4 induction by midostaurin.
-
CYP3A4 *18B and GCK G-30A polymorphisms were related to new-onset diabetes after transplantation (p < 0.05). The lower concentration/dose or fasting serum glucose was in CYP3A4 *1/*1 carriers than that in *18B/*18B carriers in all the renal transplant recipients (p < 0.05), respectively.
-
Data suggest high similarity in mechanisms involved in regulation of expression of pig CYP3A29 and human CYP3A4 in hepatocytes.
-
rs7668282 (UGT2B7, T>C) was more prevalent in sodium valproate (VPA)-resistant patients than drug-responsive patients. rs2242480 (CYP3A4, C>T) and rs10188577 (SCN1A, T>C) were more prevalent in drug-responsive patients compared to drug-resistant patients. In children with generalized seizures on VPA therapy, polymorphisms of UGT2B7, CYP3A4, and SCN1A genes were associated with seizure reduction.
